Global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Monday that it the US Food and Drug Administration (FDA) has granted tentative approval for its Abbreviated New Drug Application for Revefenacin Inhalation Solution, 175 mcg/3 mL Unit-Dose Vials.
The product is bioequivalent to Mylan's Yupelri Inhalation Solution. It is indicated for maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
According to IQVIA MAT March 2026, Revefenacin Inhalation Solution (RLD Yupelri) had estimated annual sales of USD260.7m in the United States.
Servier's Emi-Le receives US FDA breakthrough therapy designation for adenoid cystic carcinoma
Bavarian Nordic secures USD97m US vaccine contract expansion and raises 2026 outlook
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Oncopeptides plans EMA filing to broaden Pepaxti indication
GSK partners with SBP Group to accelerate China launch of bepirovirsen
Harbour BioMed's HBM7004 receives US FDA IND clearance for Phase I trial
Mabwell's clinical trial application for 9MW5211 cleared by US FDA
Innovent's IBI363 receives third Chinese regulatory BTD for MSS/pMMR CRC
European Commission approves Bristol Myers Squibb's Sotyktu for psoriatic arthritis
Rznomics receives FDA RMAT designation for HCC candidate RZ‑001
BioArctic and Eisai report FDA extension of Leqembi Iqlik review
Mezzion reveals pre-IND FDA feedback on udenafil development in ADPKD